Find News

Filter articles

Applied Filters

Showing 11 to 20 of 1063 results

MSD hit with €39m fine over contraceptive generic delay

Spain26-10-2022Staff Writer

The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

Teva breached antitrust rules over Copaxone, says EU

EU11-10-2022Sarah Speight

European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.

Generic maker hits back at Novartis stay bid

US06-10-2022Staff Writer

HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.

SCOTUS invites govt comment on Teva clash

US04-10-2022Staff writer

Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.

MSD prevails in diabetes drug dispute with Mylan

US29-09-2022Muireann Bolger

MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Federal Circuit denies Novartis’ bid to halt generics

US29-09-2022Staff Writer

Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.

Swiss pharma company reveals SCOTUS appeal plans

US22-09-2022Staff Writer

Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Big pharma firm settles HIV drug disputes with generic makers

US13-09-2022Staff Writer

Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

Generic maker urges review of $235m skinny label decision

US08-09-2022Muireann Bolger

A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.

Novartis sued over blockbuster heart failure drug

US30-08-2022Muireann Bolger

Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.

Showing 11 to 20 of 1063 results